TXA and trauma

The evidence for TXA in trauma is primarily based on the landmark Crash-2 trial, which showed a 1.5% absolute reduction in all-cause mortality. While the trial has some limitations, it has led to widespread acceptance and use of TXA in trauma resuscitation. There is also the Stamp trial, which did not show a significant mortality benefit but had a similar absolute difference as Crash-2. Overall, TXA is commonly used in trauma settings, especially in patients with significant hemorrhage or hemodynamic instability. The evidence may not be perfect, but it supports the use of TXA in trauma to potentially save lives.